{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=3", "query": { "intervention": "Cell Therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 12460, "total_pages": 1246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T22:10:38.834Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02862275", "title": "Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-05-24", "completion_date": "2026-11-21", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 8, "location_summary": "La Jolla, California • Tampa, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02862275" }, { "nct_id": "NCT07391657", "title": "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 508, "start_date": "2026-02-23", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 48, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391657" }, { "nct_id": "NCT03515512", "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-07-17", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515512" }, { "nct_id": "NCT02381067", "title": "A Prospective Study of NuCel® in Cervical Spine Fusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Spondylosis", "Spinal Stenosis", "Spondylolisthesis", "Intervertebral Disc Disease", "Intervertebral Disc Degeneration" ], "interventions": [ { "name": "NuCel with Allograft Bone", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "NuTech Medical, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 61, "start_date": "2015-03", "completion_date": "2016-12-15", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 1, "location_summary": "Marietta, Georgia", "locations": [ { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02381067" }, { "nct_id": "NCT02962167", "title": "Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medulloblastoma, Childhood, Recurrent", "Atypical Teratoid/Rhabdoid Tumor", "Medulloblastoma Recurrent" ], "interventions": [ { "name": "Modified Measles Virus", "type": "BIOLOGICAL" }, { "name": "Modified Measles Virus Lumbar Puncture", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 34, "start_date": "2017-02-22", "completion_date": "2023-05-10", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02962167" }, { "nct_id": "NCT00995007", "title": "A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Mixed Oligoastrocytoma" ], "interventions": [ { "name": "ZD6474 (Vandetanib)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 112, "start_date": "2009-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-03-29", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00995007" }, { "nct_id": "NCT05820711", "title": "Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Xerostomia" ], "interventions": [ { "name": "MSC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 23, "start_date": "2023-07-17", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05820711" }, { "nct_id": "NCT07075471", "title": "MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tenosynovial Giant Cell Tumor" ], "interventions": [], "intervention_types": [], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-09-03", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07075471" }, { "nct_id": "NCT04154956", "title": "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "SAR408701", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 389, "start_date": "2020-02-06", "completion_date": "2026-04-16", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 8, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154956" }, { "nct_id": "NCT04245722", "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "FT596", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2020-03-19", "completion_date": "2023-09-27", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-20T22:10:38.834Z", "location_count": 9, "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04245722" } ] }